2018/2019 Oncology Drug FDA Approvals Notifications Implications for Early Phase Clinical Trials Dr. Wael Harb & Wes Chapman August 18, 2019 Illustration of an immune system T cell killing a cancer cell “complete response (kum-PLEET reh-SPONTS) "The disappearance of all signs of cancer in response to treatment. [...]
Read more
Medical Oncology Practice Valuation Art and Science The Oncology Valuation Series November 27, 2018 Wes Chapman President & CEO of Verdi Oncology, Inc. “In the short run, the market is a voting machine but in the long run, it is a .” Benjamin Graham I was [...]
Read more
EBITDA What is it, and why does it matter? The Oncology Valuation Series November 21, 2018 Wes Chapman President & CEO of Verdi Oncology, Inc. My job puts me in front of physician owners of medical oncology practices at least 4-5 times per month, and invariably [...]
Read more
240% Growth in Oncology Drug Approvals in 2017 Good News for Cancer Patients Wes Chapman January 2, 2018 Introduction Advances in medical oncology depend on successful drug development – and that means successful clinical trials, leading to approval by the FDA for compounds that materially [...]
Read more
MIPS/MACRA 2018 Strategic Considerations for Medical Oncology Practices Implications of a Zero Sum Game Wes Chapman December 2017 A Doomsday Solution to a Zero Sum Game Strategic Situational Analysis MACRA/MIPS (MIPS) will become the operational standard in 2018 by which CMS evaluates: 1) The quality of care [...]
Read more